| Autor: |
Rosales Romero VG, Kravzov-Jinich J, Altagracia-Martínez M, Cook HJ |
| Zdroj: |
Journal of Pharmaceutical Finance, Economics & Policy; 2005, Vol. 14 Issue 2, p11-24, 14p |
| Abstrakt: |
Mexico, as a member of NAFTA, is committed to a high level of intellectual property protection, closely resembling to the USA and Canada in this respect. AIMS: To evaluate the development of the private Mexican generic market after the NAFTA. METHODS: A descriptive, retrospective, cross-sectional study was conducted. The IMS Mexico database was used. RESULTS: In 2003 the total Mexican pharmaceutical market (PM) represented US $9.5 billion dollars and 1.86 billion units. The total private pharmaceutical market (PPM) accounted for US$7.23 billion dollars and 930 million units. The private market (PM) includes the Rx and OTC. The total Rx PM accounted for US$5.87 billion dollars (81.19% of the total PPM) and 620 million units (66.7% of the PPM). The interchangeable generic (GI) market reached US$21 million dollars and 4.9 million units. It represented 0.22% in value of the total PM. The GI market has had an average growth of 180% per year since 1998 up to 2003. GI Ranitidine is the top-selling drug of all GIs. The GI medicines were in average 49.1% cheaper than the innovators. The generics sales projections predict that by 2008, the generic products (PM) might reach up to 1.3 billion US dollars. CONCLUSION: Mexican generic market is today characterized by various submarkets; it will take few years in order to have only GIs. The GI market is still incipient but is growing rapidly. Several governmental initiatives had enforced it and might facilitate it future development. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
